New Competitive Intelligence Report on HIV Small Molecule Therapeutics Published at MarketPublishers.com
10 Jan 2012 • by Natalie Aster
LONDON – Despite a high current standard of care in antiretroviral therapy for HIV, multidrug-resistant strains continue to emerge, underscoring the need for additional novel mechanism inhibitors that will offer expanded therapeutic options in the clinic.
New research report “Competitor Analysis: HIV Small Molecule Therapeutics” worked out by La Merie Publishing has been recently published by Market Publishers Ltd.
Competitor Analysis: HIV Small Molecule Therapeutics
Published: December, 2011
Price: US$ 642,00
The report presents a competitor evaluation in the field of marketed products and R&D projects of HIV small molecule therapeutics. It is also supplemented with a list of company-specific product portfolios and R&D pipelines of HIV small molecule therapeutics.
Competitor projects are listed in a tabular format providing information on:
- drug codes;
- target/mechanism of action;
- class of compound;
- product category;
- R&D stage;
- additional comments with a hyperlink leading to the source of information.
More new competitive intelligence reports and other studies by the publisher can be found at La Merie Publishing page.